These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30105842)

  • 21.
    Zhang Q; Cheng L; Qin Y; Kong L; Shi X; Hu J; Li L; Ding Z; Wang T; Shen J; Yang Y; Yu L; Liu B; Liu C; Qian X
    Clin Transl Immunology; 2021; 10(10):e1347. PubMed ID: 34729183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining bioinformatics and biological detection to identify novel biomarkers for diagnosis and prognosis of pulmonary tuberculosis.
    Zhao G; Luo X; Han X; Liu Z
    Saudi Med J; 2020 Apr; 41(4):351-360. PubMed ID: 32291421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
    Zhang C; Li J; Wang H; Song SW
    Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
    Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
    World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
    Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
    J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor Purity as an Underlying Key Factor in Glioma.
    Zhang C; Cheng W; Ren X; Wang Z; Liu X; Li G; Han S; Jiang T; Wu A
    Clin Cancer Res; 2017 Oct; 23(20):6279-6291. PubMed ID: 28754819
    [No Abstract]   [Full Text] [Related]  

  • 28. Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients.
    Guo Q; Guan GF; Cheng W; Zou CY; Zhu C; Cheng P; Wu AH
    CNS Neurosci Ther; 2019 Mar; 25(3):343-354. PubMed ID: 30311408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas.
    Hou C; Ishi Y; Motegi H; Okamoto M; Ou Y; Chen J; Yamaguchi S
    J Neurooncol; 2019 Nov; 145(2):201-210. PubMed ID: 31506754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
    Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
    World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Migration of myeloid cells during inflammation is differentially regulated by the cell surface receptors Slamf1 and Slamf8.
    Wang G; van Driel BJ; Liao G; O'Keeffe MS; Halibozek PJ; Flipse J; Yigit B; Azcutia V; Luscinskas FW; Wang N; Terhorst C
    PLoS One; 2015; 10(3):e0121968. PubMed ID: 25799045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of an energy metabolism-related signature associated with clinical prognosis in diffuse glioma.
    Zhou Z; Huang R; Chai R; Zhou X; Hu Z; Wang W; Chen B; Deng L; Liu Y; Wu F
    Aging (Albany NY); 2018 Nov; 10(11):3185-3209. PubMed ID: 30407923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
    Lin L; Wang G; Ming J; Meng X; Han B; Sun B; Cai J; Jiang C
    Tumour Biol; 2016 Nov; 37(11):15333-15339. PubMed ID: 27704357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
    Wang H; Jiang C
    Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.
    Guan X; Zhang C; Zhao J; Sun G; Song Q; Jia W
    EBioMedicine; 2018 Sep; 35():233-243. PubMed ID: 30131308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An NF-κB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells.
    Ius T; Ciani Y; Ruaro ME; Isola M; Sorrentino M; Bulfoni M; Candotti V; Correcig C; Bourkoula E; Manini I; Pegolo E; Mangoni D; Marzinotto S; Radovic S; Toffoletto B; Caponnetto F; Zanello A; Mariuzzi L; Di Loreto C; Beltrami AP; Piazza S; Skrap M; Cesselli D
    Neuro Oncol; 2018 May; 20(6):776-787. PubMed ID: 29228370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long noncoding RNA LINC00152 is a potential prognostic biomarker in patients with high-grade glioma.
    Wang W; Wu F; Zhao Z; Wang KY; Huang RY; Wang HY; Lan Q; Wang JF; Zhao JZ
    CNS Neurosci Ther; 2018 Oct; 24(10):957-966. PubMed ID: 29577647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune and Clinical Features of
    Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
    Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bromodomain PHD‑finger transcription factor promotes glioma progression and indicates poor prognosis.
    Pan Y; Yuan F; Li Y; Wang G; Lin Z; Chen L
    Oncol Rep; 2019 Jan; 41(1):246-256. PubMed ID: 30542695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.